Camizestrant Significantly Delayed Disease Progression in Advanced ER-Positive Breast Cancer, Adding at Least 3.5 Months Benefit versus Faslodex

SERENA-2 Phase II trial showed AstraZeneca’s camizestrant demonstrated a statistically significant and clinically meaningful improvement in progression-free survival at both 75mg and 150mg dose levels versus Faslodex 500mg in post-menopausal patients with estrogen receptor (ER)-positive locally advanced or metastatic breast cancer.